The report provides trends prevailing in the global cell line development serum market, and the drivers and hindrances pertaining to the market growth.
According to our latest study on “Cell Line Development Serum Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Type and Application,” the market is expected to reach US$ 1,467.92 million by 2027 from US$ 915.58 million in 2019; it is estimated to grow at a CAGR of 6.1% from 2020 to 2027. The report provides trends prevailing in the global cell line development serum market, and the drivers and hindrances pertaining to the market growth.
Regenerative medicines have the potential to replace or heal tissues, as well as organs, and normalize congenital defects. Certain age-related abnormalities, diseases, and trauma damage the tissues and organs. Over the last decade of a century, the tissue engineering industry has emerged impressively, and it has now evolved into the broader area of regenerative medicine, which focuses on the development of clinical therapies for the maintenance, repair, replacement, and enhancement of biological function, with the use of cell engineering. Cell line development is a crucial and invariable part of regenerative medicine. Thus, advancements in the regenerative medicine boost the demand for serum used in cell line development.
Request for sample Research on Cell Line Development Serum Market study at: https://www.theinsightpartners.com/sample/TIPRE00015863/
Cell Line Development Serum Market Competitive analysis and Landscape
Lonza, Thermo Fisher Scientific Inc., Sigma-Aldrich Corporation (MERCK KGaA), Cytiva (Danaher), PAN Biotech, Corning Incorporated, European Collection of Cell Cultures (ECACC), Bovogen Biologicals Pty Ltd., WuXi AppTec, and American Type Culture Collection (ATCC) are among the leading companies operating in the cell line development serum market.
Increasing adoption of regenerative medicines and rising R&D investments and collaborations among by pharmaceutical and biotechnology companies treatments are the key factors driving the growth of the cell line development serum market. Moreover, increasing vaccine production is likely to have positive impact on the market in the coming years. However, risk of contamination, misidentification, and random alternations in cell lines are restricting the market growth.
Increasing Adoption of Regenerative Medicines
Regenerative medicines have the potential to replace or heal tissues, as well as organs, and normalize congenital defects. Certain age-related abnormalities, diseases, and trauma damage the tissues and organs. Over the last decade of a century, the tissue engineering industry has emerged impressively, and it has now evolved into the broader area of regenerative medicine, which focuses on the development of clinical therapies for the maintenance, repair, replacement, and enhancement of biological function, with the use of cell engineering. Cell line development is a crucial and invariable part of regenerative medicine. Thus, advancements in the regenerative medicine boost the demand for serum used in cell line development.
Cell lines are instrumental in testing and development of drugs, development of cell-based therapy, and research related to cancer tissues, among other applications. New drugs developed in pharmaceutical companies are safely and effectively tested on differentiated stem cells for checking their potential. Further, the regenerative medicines using cell-based models have the potential to help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, surge in the use of regenerative medicines propels the cell line development serum market.
Cell lines play a major role in testing and development of drugs, development of cell-based therapy, and research related to cancer tissues, among other applications. New drugs developed in pharmaceutical companies are safely and effectively tested on differentiated stem cells for checking their potential. Further, the regenerative medicines using cell-based models have the potential to help the researchers in early-intervention treatment for degenerative diseases and traumatic injuries. Thus, surge in the use of regenerative medicines propels the cell line development serum market.
Cell Line Development Serum Market Segmentation Review
Based on type, the global cell line development serum market is segmented into fetal bovine serum, adult bovine serum, porcine serum, horse serum, other animal serum. Fetal bovine serum segment held the largest share of the market in 2019 and is expected to register the highest CAGR of the market during the forecast period. Fetal bovine serum (FBS) derived from the blood drawn from a bovine fetus through a closed collection system from the slaughterhouse. FBS is the most widely used serum-supplement for the in vitro cell culture of eukaryotic cells. This is because it has a deficient level of antibodies and contains more growth factors, allowing for versatility in different cell culture applications.
Based on application, the global cell line development serum market is segmented into tissue engineering and regenerative medicines, toxicity testing, research, drug discovery, bioproduction. In 2019, the bioproduction segment held the largest share of the market; whereas, the drug discovery segment is expected to register the highest CAGR in the market during the forecast period.
Purchase Full Copy of Cell Line Development Serum Market Study at: https://www.theinsightpartners.com/buy/TIPRE00015863/
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876